KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease.

Pauline Wils, Vipul Jairath, Bruce E Sands, Fernando Magro, Walter Reinisch, David Rubin, Silvio Danese, Cédric Baumann, Laurent Peyrin-Biroulet

United European Gastroenterol J 11(8) 797-806

PMID37670487
PMCIDPMC10576605
DOI10.1002/ueg2.12455
发表日期2023-09-06
摘要

摘要

BACKGROUND AND AIMS: The accumulation of multiple randomized controlled trials in the field of inflammatory bowel diseases provides an opportunity to compare treatment effects between phase 2 and 3 trials. We aimed to determine whether treatment effects observed in phase 3 investigating biologics and small molecule drugs differed from those in their preceding phase 2 trial. METHODS: We first performed a review of phase 2 and phase 3 trials enrolling ulcerative colitis (UC) or Crohn's disease (CD) patients. We compared the percent overall success for key endpoints between phases (several phase 3 could be matched to a single phase 2 trial). Then, we compared the percent overall success in the matched phase 2 and 3 trials (ratio 1:1), and performed sensitivity analysis. RESULTS: We identified 14 phase 2 (8 CD; 6 UC) and 24 phase 3 (13 CD; 11 UC) trials. In CD, the different analyses suggest that the percentage of overall success of clinical remission and clinical response was significantly higher in phase 2 than in phase 3 trials. In UC, the analyses suggest collectively that the percent of treatment effect seemed similar for clinical remission, clinical response and histologic outcomes between phases but with a lower percentage of overall success in phase 2 than in phase 3 trials for endoscopic endpoints. CONCLUSIONS: In UC, we observed a similar percentage of treatment effect for clinical and histologic outcomes between phase 2 and 3 trials but not for endoscopic outcomes. Whereas in CD, we showed a failure to reproduce similar results between phases. These results may help sponsors in the design of future drug development programs.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。